changes in rates of protein turnover during regression of thyroxine-induced left ventricular hypertrophy, New Zealand White rabbits received intravenous thyroxine (200 pg/kg/d) for 9 days. Thyroxine was withheld, and in uiuo protein turnover was evaluated on the IOth, 15th and 20th days. Animals not receiving thyroxine served as controls. Heart rate, blood pressure, and rate-pressure product were measured to correlate changes in cardiac work with protein turnover rates during the development and regression of hypertrophy.
Thyroxine administration produced left ventricular hypertrophy by increasing the rate of protein synthesis (from 37.9 + 8.9 to 64.1 f 15.3 mg/day; P < 0.05) to a greater degree than protein degradation (from 29.8 + 8.9 to 48.2 f 15.3 mg/day for control and thyroxine-treated animals, respectively; P < 0.05). Cessation of thyroxine administration resulted in an eventual return of left ventricular mass to that of normally growing control animals. The major observation noted during thyroxine withdrawal was a return of protein synthetic rates to normal. Absolute rates ofprotein degradation remained elevated, whereas fractional protein degradative rates (i.e. the fraction of total protein degraded per day) were unchanged by the administration and withdrawal of thyroxine.
These results indicate that suppression of both physiological and hormone-induced growth following cessation of thyroxine resulted from a decrease in cardiac protein synthetic rates and an increased rate of flux through the protein degradative pathway(s), while fractional rates of protein degradation (and thus average protein half-life) remained unchanged. The development and regression of thyroxine-induced hypertrophy correlated with thyroxine-mediated alterations in cardiac work.
Introduction
Hypertrophy is an adaptive response of ventricular myocardium to a variety of physiological and pathological stimuli. Removal of the stimulus responsible for the growth process usually results in a return of cardiac mass to normal.
For example, regression of cardiac hypertrophy following reversal of chronic left ventricular pressure overload has been demonstrated in both experimental animals and man (Beznak et al., 1969; Pandis et al., 1984) .
Experimental models of chronic volume overload have been less extensively studied, but replacement of the aortic valve in humans with aortic insufficiency has often, but not always, been associated with a return of ventricular mass towards normal (Pandis et al., 1984) . The intracellular mechanisms responsible for the regression of myocardial hypertrophy are poorly understood, but must ultimately depend upon changes in the opposing processes of cardiac protein synthesis and de-gradation.
Alterations in the rates of one or both of these processes must explain the cessation of the growth process and the regression of myocardial protein mass. Thyroxine administration is a reproducible and extensively studied model for the development of cardiac hypertrophy.
We have previously shown that thyroxine-induced cardiac hypertrophy is associated with both increased fractional and absolute rates of in vivo protein synthesis, as well as increases in the efficiency and capacity for protein synthesis (Parmacek et al., 1986) . Measurements of protein degradative rates in this hormone induced model of hypertrophy vary, but in all cases, hypertrophy occurs because the accelerated rate of new protein synthesis exceeds the rate of degradation (Morgan et al., 1987) . Regression of thyroxine-induced cardiac hypertrophy has been less extensively studied. In isolated, perfused rat hearts studied 4 days after the cessation of thyroxine administration, Sanford et al. (1978) demonstrated regression of myocardial mass that was associated with a decrease in both the fractional rates of cardiac protein synthesis and degradation. However, due to methodological difficulties in assessing in vitro rates of protein degradation, direct comparisons of the rates of protein synthesis and degradation during regression could not be made. Therefore, these in vitro studies did not define to what extent each process contributes to the regression of cardiac hypertrophy in vivo following the cessation of thyroxine administration. The proximal stimulus responsible for accelerated protein synthesis in excess of degradation during thyroxine administration remains unclear. Thyroxine interacts with nuclear receptors to induce the synthesis of a variety of new cardiac proteins, including amyosin heavy chain (Zak et al., 1982; Klein, 1988; Everett et al., 1984; Gustafson et al., 1986) . In addition, thyroxine treatment alters peripheral hemodynamics, thus changing the loading conditions of the left ventricle. Recent evidence has emphasized the importance of cardiac work necessary for the development of hypertrophy during thyroxine administration (Klein et al., 1986; Korecky et al., 1987 /kg ) for 9 days. Hormone administration was then discontinued, and the animals were randomly assigned to regression groups (R-0, R-l, R-3, R-5, R-7 and R-IO). The R-0 group consisted of rabbits that had not received thyroxine for 24 h, and were considered to have undergone no regression from thyroxine-induced cardiac hypertrophy. In the remaining thyroxine-treated animals, cardiac hypertrophy was subsequently allowed to regress for 1, 3, 5, 7 and 10 days, respectively.
Each group consisted of a minimum of four animals. Rabbits were housed and fed ad libitum, as previously described (Samarel et al., 1981 
VI. Determination of ventricular tissue composition
All animals were killed by an intravenous injection of an overdose of sodium pentobarbital. The heart was rapidly excised via a median sternotomy incision and placed into 150 mM NaCl (4°C) to remove blood. The heart was blotted dry, trimmed of fat and major blood vessels, and weighed. After determination of total heart weight, the atria and right ventricular free wall were excised. The LV, consisting of the left ventricular free wall and septum, and the right ventricle (RV Total RNA concentration was analyzed by the method of Munro and Fleck ( 1966) . DNA concentration was assessed using a minor modification of the method of Cesarone et al. ( 1979) . Results were expressed both as mg of total RNA or DNA per gram LV wet weight, and as mg of total protein or RNA per mg of total DNA.
VII. Determination of leucine specijic radioactivity in plasma and LV total protein fractions Leucine specific radioactivity in the plasma and in TCA-precipitable total cardiac protein (TCP) was determined as previously described (Parmacek et al., 1986) .
VIII. Calculation of LV total cardiac protein fractional synthetic rates
The fractional synthetic rates (K,, %/day) of LV TCP were calculated for each animal using the formula described by Everett et al. (1979) :
where P* is the leucine specific radioactivity in LV TCP (dpmlnmol), F is the leucine specific radioactivity in the plasma at the end of the infusion (dpm/nmol), and Xr is the first order rate constant (days-') describing the rate of rise of plasma leucine specific radioactivity to plateau (pm, values were determined for each infusion experiment by non-linear, non-weighted regression analysis, as previously described (Parmacek et al., 1986) . This method assumes that the. specific radioactivity of leucyl-tRNA (the immediate precursor for protein synthesis) rapidly and completely equilibrates with the plasma leucine specific radioactivity in all experimental groups.
IX. Calculation ofplasma Eeucinejux
Plasma leucine flux, an estimate ofwhole body protein synthesis (Water-low and Stephen, 1967; Garlick et al., 1975) , was calculated for each infusion animal using the following formula: leucine flux @mol/h) = infusion rate (@i/h) &$&Ci/~mol) / 100 g body weight X. Determination of LV total cardiac protein accumulation rates
Values of LV TCP accumulation rates (Rs) for control and thyrotoxic rabbits had been published in our previous studies of thyroxineinduced left ventricular hypertrophy (Parmacek et al., 1986; Samarel et al., 1987) . LV TCP accumulation rates (Rs) in the regression animals of the present study were directly determined from measurements of LV TCP and heart weight. Mean LV TCP content was plotted vs. days of regression. Sequential fitting of the data to first, second and third degree polynomial equations was then performed and the improvement in fit was assessed by the significance of the partial F-value for the parameter of highest degree. 
Results

I. Cardiac growth during administration and withdraw1 of thyroxine
Sixty-nine rabbits were used to assess myocardial growth and composition after administration and withdrawal of thyroxine (Table  1) . Initial body weights for all animals were similar. Administration of thyroxine for 9 days (R-O animals) resulted in a 20% decrease in body weight as compared to C-O animals. By the fifth day after cessation of hormone administration, the thyroxine-induced weight loss had resolved, and the animals continued to gain weight through the 10th day following hormone withdrawal. Cardiac hypertrophy was evident after 9 days of thyroid hormone, as reflected by a 25% increase in total heart weight. Proportional increases in RV and LV weights were observed. Total heart weight remained relatively constant following withdrawal of thyroxine.
In the R-O animals, the New Zealand White rabbits were given intravenous thyroxine (200 yg/kg/day) for 9 days. Thyroxine was stopped, and regression allowed to occur for 0, 1, 3,5,7, and 10 days (R-O, R-l, R-3, R-5, R-7, and R-10, respectively).
Animals not receiving thyroxine served as controls (C-0 total heart weight to body weight ratio increased 56% as compared to C-O rabbits. By the fifth day following discontinuation of thyroxine, the total heart weight to body ratio was significantly less than R-O and R-3 values and continued to decrease through day 10 of regression. Given the relative constant values for total heart weight, decreases in total heart weight to body weight ratios seen after cessation of thyroxine administration were largely the result of increases in body weight.
II. Physiological changes associated with administration and withdrawal of thyroxine
The results of physiological measurements made during the treatment protocol are depicted in Figure 2 . A significant increase in heart rate was observed during the course of thyroxine administration (260 + 22 vs. 360 + 35 beats/min for CO and R-6 animals, respectively; P < 0.05). The mean heart rate remained significantly elevated in R-3 et al., 1983) . Thus, the data in Figure 2 indicate that administration of thyroxine resulted in an increase in cardiac work that appeared to resolve within 3 to 5 days following cessation of the hormone.
III. [ 3 Hlleucine infusion experiments
[3H]leucine infusions were performed on a subset of 32 rabbits. Each of the four groups of animals used in the infusion experiments consisted of 8 randomly selected rabbits from the GO, R-O, R-5, and R-10 groups. E,, and EC, were found to be similar in all groups (Table  2) . However, plasma leucine flux (an index of whole-body protein synthesis) was significantly elevated in R-O animals and returned to the rate observed in C-O animals within 5 days after hormone withdrawal (Table 2 ). These changes in plasma leucine flux paralleled changes in the indices of cardiac work as described above (Fig. 2) .
IV. Total andfree thyroxine levels following administration and withdrawal of thyroxine Following administration of thyroxine for 9 days (R-O animals), plasma concentrations of both total and free thyroxine were significantly elevated compared to C-O animals ( Table 3) . Cessation of thyroxine administration for 5 days resulted in a significant decrease in total thyroxine concentration below that of controls. By the 10th day, plasma total thyroxine concentration had returned to control values. In a similar fashion free thyroxine concentration fell by the 5th day after discontinuing thyroxine but returned to control values by day 10; however, the transient decrease in free thyroxine concentration was not statistically significant.
V. Eflects of thyroxine administration and withdrawal on left ventricular tissue composition
The cardiac growth seen during thyroxine administration was associated with an increase in the capacity for protein synthesis as assessed by the total tissue RNA concentration, expressed as mg/g LV wet weight (Table 4) . Total tissue RNA concentration returned to the level observed in C-O animals (Parmacek et al., 1986; Samarel et al., 1987) . Thus, the TCP R, for control and thyrotoxic rabbits were 8.1 and 15.9 mg/day, respectively (Table  5) . Five days following cessation of hormone administration, the TCP R, decreased to 0.6 mg protein/day.
Based on this analysis, TCP R, was reduced to less than 10% of the value observed for normally growing control animals (i.e. 8.1 mg/day). We conclude that this marked reduction in the TCP R, is consistent with regression of LV hypertrophy despite a continued (albeit negligible) accumulation of protein following cessation of hormone administration. These values were subsequently used to calculate the instantaneous fractional rate of LV TCP accumulation (K,) in the C-O, R-O, R-5, and R-10 animals used in protein synthesis experiments (Table 5 ). These calculations indicate that administration of thyroxine for 9 days resulted in a significant increase in TCP X, when compared to controls. Upon discontinuation of thyroxine a marked suppression of TCP Ks values below both C-6 and R-O levels were observed in the R-5 and R-10 animals.
VII. Alterations in LVgrotein synthesis and degradation during administration and withdrawal of thyroxine Data depicting alterations in LV TCP turnover during administration and withdrawal of thyroxine are also depicted in Table 5 . Increased rates of both LV TCP R, and TCP Rd were evident after 9 days of thyroxine administration. The accelerated accumulation of LV TCP in R-O animals was due to the greater increase in the rate of TCP R, compared to TCP Rd. Cessation of thyroxine administration resulted in a return of the TCP R, to that observed in C-O animals, whereas the TCP Rd remained elevated. Thus, return of the synthetic rate to C-O levels in conjunction with the persistently elevated degradative rate resulted in a negligible rate of TCP accumulation (i.e. a cessation of both hormone-induced and normal growth).
After 9 days of thyroxine administration, the efficiency of protein synthesis, expressed as mg TCP synthesized/day/mg RNA, was not significantly different ' from C-O animals (Table 5) . Synthetic efficiency remained unchanged following cessation of hormone administration.
Data were also analyzed in terms of fractional rates of protein synthesis (X,) and degradation (Xd). Following administration of thyroxine for 9 days the TCP K, values were significantly elevated as compared to C-O animals. Discontinuation of thyroxine resulted in a return of TCP K, values to that observed in GO animals.
In contrast, TCP & was not Experimental animals were given intravenous thyroxine (200 pg/kg/d) for 9 days. Thyroxine was stopped and regression allowed to occur for 0,5, and 10 days (R-O, R-5, and R-10, respectively). significantly different after 9 days of thyroxine administration and remained at C-O levels following cessation of hormone administration. We interpret these results as indicating that removal of the stimulus for thyroxineinduced cardiac hypertrophy was not associated with an increased susceptibility of mixed cardiac proteins to proteolysis.
Animals not receiving thyroxine served as controls (C-O). 4, Rs
Thus, regression of thyroxine-induced hypertrophy was not accompanied by a significant reduction in the average half-life of mixed cardiac proteins.
Discussion
The administration of thyroxine in the rabbit produces cardiac hypertrophy in viuo by increasing protein synthetic rates to a greater degree than degradative rates, resulting in the net accumulation of cardiac protein (Parmacek et al., 1986 et al., 1975) . Thus, despite the low concentrations of free and total thyroxine following the cessation of hormone administration, there was an accelerated increase in body weight, suggesting that this weight gain occurred independent of plasma thyroxine concentrations.
The methods employed to estimate fractional rates of protein synthesis and degradation are based on the assumption that during constant intravenous infusion of E3H]leucine there is rapid and complete equilibration between leucyl-tRNA and plasma leucine. We have previously demonstrated in both untreated rabbits and rabbits treated with thyroxine for 3 days that plasma leucine specific radioactivity and cardiac leucyl-tRNA specific radioactivity are nearly identical following a constant infusion of [3H]leucine (Parmacek et al., 1986) . Thus, plasma leucine specific radioactivity accurately reflects the cardiac leucyl-tRNA pool and is acceptable for use in the calculation of fractional protein synthetic rates for both thyroxine-treated and untreated control animals. However, it is possible that during regression of thyroxine-induced cardiac hypertrophy this relationship is altered, leading to a systematic underestimation of total protein fractional synthetic rates.
Our results support the findings of previous investigators regarding the effect of thyroxine administration on protein synthesis during the development of cardiac hypertropty (Bonnin et al., 1983; Carter et al., 1982; Parmacek et al., 1986; Crie et al., 1983) . We demonstrated a 70% increase in the TCP R, and a 62% increase in the TCP Rd following thyroxine administration; values similar to those previously reported by this laboratory (Parmacek et al., 1986) . Our present data also indicate that, in addition to increasing rates of protein turnover, thyroxine administration resulted in hemodynamic alterations that increased cardiac work. The temporal relationship between increased cardiac work, augmented rates of protein synthesis, and the development of cardiac hypertrophy strongly supports recent observations regarding the relative importance of thyroxine mediated changes in cardiac work vs. the direct effects of thyroxine on nyocardial protein metabolism (Klein, 1988; Klein et al., 1986; Koreckey et al., 1987) . Thus, our results suggest that thyroxine-mediated alterations in cardiac work play a significant role in modulating rates of protein synthesis required for the development of cardiac hypertrophy.
Following cessation of thyroxine administration, we demonstrated:
(a) reduced TCP synthetic rates (R,); (b) the return of indices of cardiac work to control levels, and (c) the cessation of both normal and hormoneinduced growth. We defined regression as a return of LV TCP mass towards that of agematched controls. Since juvenile animals were used throughout the study period, cardiac mass was continually increasing in the control population due to physiologic growth. Thus, regression may have resulted from one of two mechanisms: (a) an absolute decrease in LV TCP mass or (b) a decreased TCP R, compared to normally growing control animals. Our data support the latter mechanism and show that LV TCP mass did not change upon cessation of hormone administration, but eventually reached a value equal to that of the control group. Thus, regression of thyroxineinduced cardiac hypertrophy was mediated, in part, by a return of the increased TCP R, back to normal. These results in the rabbit differ somewhat from observations of thyroxine-induced cardiac hypertrophy in rats. Previous investigators using rats have shown an absolute decrease in both heart weight (Sanford et al., 1978; Campbell and Gerdes, 1988) and cardiomyocyte volume (Campbell and Gerdes, 1988) following cessation of thyroxine administration.
These observations may reflect age, sex, and/or species differences between the experimental models.
Changes in protein synthetic rates can result from either altered protein synthetic efficiency and/or capacity (Morgan et al., 1987) . We previously demonstrated that LV protein synthetic efficiency was augmented after 3 days of thyroxine administration, but returned to control levels by day 9 of hormone treatment. Conversely, the capacity for protein synthesis was unchanged after 3 days of hormone administration, but was significantly increased by the second week of thyroxine treatment (Parmacek et al., 1986) . Similar alterations in cardiac protein synthetic eficiency and capacity in vivo have been demon-strated during the development of right ventricular hypertrophy due to pulmonary artery banding (Nagai et al., 1988) . In contrast, Siehl et al., (1985) demonstrated no change in protein synthetic efficiency in their in vitro studies of thyroxine-induced rat cardiac hypertrophy. They reported a more modest increase in protein synthesis (25% above control in their study) following daily administration of thyroxine for 4 days. However, protein synthetic rates were measured in both the control and thyroxine treated animals using an isolated, perfused working heart preparation under identical conditions of temperature, coronary flow, aortic perfusion pressure, and substrate supply. Thus, the thyroxine-induced alterations in body temperature and ventricular loading (which we have demonstrated to occur in viuo in response to thyroxine)
were not simulated.
Therefore, their contribution to accelerated protein synthesis and protein synthetic efficiency were not assessed in the study by Siehl et al. ( 1985) .
In contrast to changes demonstrated during the development of thyroxine-induced hypertrophy, regression was not associated with alterations in protein synthetic efficiency, although a reduction in capacity (as evidenced by a return of total RNA concentration to control values) was observed. Nevertheless, removal of the stimulus for hormone-induced growth affected both total protein and RNA turnover. Whether the reduction in RNA concentration and content that accompanied regression was the result of decreased synthesis, or increased degradation of myocyte ribosomal RNA requires additional investigation.
We did not demonstrate a change in the total DNA concentration or total protein to DNA ratio during the development or regression of thyroxine-induced left ventricular hypertrophy.
These data indicate that, in the absence of polyploidy, some degree of hyperplasia occurred. Similar results were noted by Parmacek et al. (1986) 
